Sunitinib malateIZZEDINE, Hassane; BUHAESCU, Irina; RIXE, Olivier et al.Cancer chemotherapy and pharmacology. 2007, Vol 60, Num 3, pp 357-364, issn 0344-5704, 8 p.Article

Lower Limbs Erosions Induced by SunitinibKLUGER, Nicolas; CHAPELLE, Angélique; JACOT, William et al.Acta dermato-venereologica. 2011, Vol 91, Num 3, pp 360-361, issn 0001-5555, 2 p.Article

Sunitinib-induced hand―foot syndrome: a new, distinct formFIFE, D. J; WU, J. J; BEHNAM, S. E et al.Clinical and experimental dermatology (Print). 2010, Vol 35, Num 2, pp 200-201, issn 0307-6938, 2 p.Article

Erupción simulando pápulas de Gottron inducida por sunitinib = Gottron-Like Papules Induced by SunitinibMARTORELL-CALATAYUD, A; SANMARTIN, O; TRAVES-ZAPATA, V et al.Actas dermo-sifiliográficas (Ed. impresa). 2011, Vol 102, Num 5, pp 385-387, issn 0001-7310, 3 p.Article

Surrogate biomarkers in evaluating response to anti-angiogenic agents : focus on sunitinibDEPRIMO, S. E; BELLO, C.Annals of oncology. 2007, Vol 18, issn 0923-7534, x11-x19, SUP10Conference Paper

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinibLEE, W. J; LEE, J. L; CHANG, S. E et al.British journal of dermatology (1951). 2009, Vol 161, Num 5, pp 1045-1051, issn 0007-0963, 7 p.Article

New challenges in kidney cancer therapy : sunitinibIZZEDINE, H; BILLEMONT, B; THIBAULT, F et al.Annals of oncology. 2007, Vol 18, issn 0923-7534, ix83-ix86, SUP9Conference Paper

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. CommentaryJOENSUU, Heikki; CHU, Tammy F; DESAI, Jayesh et al.Lancet (British edition). 2007, Vol 370, Num 9604, issn 0140-6736, 1978-1980, 2011-2019 [12 p.]Article

Kutane Nebenwirkungen der Multikinaseinhibitoren Sorafenib und Sunitinib : Neue kutane Arzneimittelnebenwirkunger = Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib : New cutaneous side effects of drugsWOLLENBERG, A; STAEHLER, M; EAMES, T et al.Der Hautarzt. 2010, Vol 61, Num 8, pp 662-667, issn 0017-8470, 6 p.Article

Sunitinib Produces Neuroprotective Effect Via Inhibiting Nitric Oxide OverproductionWEI CUI; ZHANG, Zai-Jun; HAN, Yi-Fan et al.CNS neuroscience & therapeutics (Print). 2014, Vol 20, Num 3, pp 244-252, issn 1755-5930, 9 p.Article

When a thymic carcinoma becomes a GISTROSSI, Valentina; DONINI, Maddalena; SERGIO, Pietro et al.Lung cancer. 2013, Vol 80, Num 1, pp 106-108, issn 0169-5002, 3 p.Article

Differential drug class―specific metastatic effects following treatment with a panel of angiogenesis inhibitorsCHUNG, Alicia S; KOWANETZ, Marcin; XIUMIN WU et al.Journal of pathology (Print). 2012, Vol 227, Num 4, pp 404-416, issn 0022-3417, 13 p.Article

A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasmaETIENNE-GRIMALDI, Marie-Christine; RENEE, Nicole; IZZEDINE, Hassan et al.Journal of chromatography. B. 2009, Vol 877, Num 29, pp 3757-3761, issn 1570-0232, 5 p.Article

A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancerHAN, Ji-Youn; HYAE YOUNG KIM; KUN YOUNG LIM et al.Lung cancer. 2013, Vol 79, Num 2, pp 137-142, issn 0169-5002, 6 p.Article

Marginal increase of sunitinib exposure by grapefruit juiceVAN ERP, Nielka P; BAKER, Sharyn D; ZANDVLIET, Anthe S et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 3, pp 695-703, issn 0344-5704, 9 p.Article

A biodegradable perivascular wrap for controlled, local and directed drug deliverySANDERS, William G; HOGREBE, Paul C; GRAINGER, David W et al.Journal of controlled release. 2012, Vol 161, Num 1, pp 81-89, issn 0168-3659, 9 p.Article

Posterior reversible encephalopathy syndrome during sunitinib therapyCUMURCIUC, R; MARTINEZ-ALMOYNA, L; HENRY, C et al.Revue neurologique (Paris). 2008, Vol 164, Num 6-7, pp 605-607, issn 0035-3787, 3 p.Article

Anti―VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour modelsSINGH, Mallika; COUTO, Suzana S; NANNINI, Michelle A et al.Journal of pathology (Print). 2012, Vol 227, Num 4, pp 417-430, issn 0022-3417, 14 p.Article

Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effectSTACCHIOTTI, S; NEGRI, T; CASALI, P. G et al.Annals of oncology. 2011, Vol 22, Num 7, pp 1682-1690, issn 0923-7534, 9 p.Article

Advances in the treatment of gastrointestinal stromal tumoursJUDSON, I; DEMETRI, G.Annals of oncology. 2007, Vol 18, issn 0923-7534, x20-x24, SUP10Conference Paper

A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activitiesCHRISTENSEN, J. G.Annals of oncology. 2007, Vol 18, issn 0923-7534, x3-x10, SUP10Conference Paper

Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancerSPIGEL, David R; GRECO, F. Anthony; RUBIN, Mark S et al.Lung cancer. 2012, Vol 77, Num 2, pp 359-364, issn 0169-5002, 6 p.Article

Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management : TARGETED THERAPY TOXICITIESBROWN, Rebecca L.Targeted oncology. 2011, Vol 6, Num 4, pp 217-226, issn 1776-2596, 10 p.Article

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off periodBRITTEN, Carolyn D; KABBINAVAR, Fairooz; HECHT, J. Randolph et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 3, pp 515-524, issn 0344-5704, 10 p.Article

Stability of Sunitinib in Oral SuspensionNAVID, Fariba; CHRISTENSEN, Robbin; MINKIN, Patton et al.The Annals of pharmacotherapy. 2008, Vol 42, Num 7-8, pp 962-966, issn 1060-0280, 5 p.Article